Walls, M., Baxi, S.M., Mehta, P.P., Liu, K.K.C., Zhu, J.J., Estrella, H., Li, C.Z., Zientek, M., Zong, Q., Smeal, T. and Yin, M.J. (2014) Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Se-
lective Oral PI3K Inhibitor PF-4989216. Clinical Cancer Research, 20, 631-643. http://dx.doi.org/10.1
158/1078-0432.CCR-13-1663

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.